Tesamorelin and CJC-1295 are both GHRH analogues, which makes this comparison genuinely different from the ipamorelin pairing covered elsewhere in this catalog. Same receptor family, different specific compound, and Healio stocks only one of them.
This guide covers what separates the two structurally, why CJC-1295 is often discussed with an additional modification attached, what each has been studied for, and Healio’s position on CJC-1295 specifically. Nothing here is guidance for personal use.
Tesamorelin vs CJC-1295: same receptor family, different compound
Both are synthetic analogues of growth hormone releasing hormone, acting on the same GHRH receptor pathway covered in growth hormone peptide research. Unlike the tesamorelin-versus-ipamorelin comparison, which involves genuinely separate receptor pathways, this pairing involves two different engineering approaches to the same target.
| Tesamorelin | CJC-1295 | |
|---|---|---|
| Receptor | GHRH receptor | GHRH receptor |
| Approval status | Approved for one narrow indication | No approved formulation |
| Stocked at Healio | Yes | No |
Why CJC-1295 is often discussed with a modification attached
CJC-1295 is frequently referenced alongside a further structural modification intended to extend its duration even beyond typical GHRH analogue persistence, sometimes discussed as a distinct variant. This kind of layered modification, extending an already-engineered molecule further, is the same general engineering pattern seen across this compound family, applied here to push duration further still.
Different presentations and modifications circulating under the CJC-1295 name are not necessarily identical products, which is worth knowing before assuming any two sources describing CJC-1295 are discussing the same specific molecule.
Why tesamorelin has an evidence advantage despite the shared mechanism
Sharing a receptor target does not mean sharing an evidence base. Tesamorelin underwent a full clinical development program specifically targeting visceral abdominal fat in HIV-associated lipodystrophy, resulting in approval for that narrow indication, covered in the tesamorelin monograph.
CJC-1295 has not undergone comparable clinical development and holds no approved formulation. What exists is early-phase work in healthy adults, reporting sustained rises in growth hormone and IGF-I after subcutaneous dosing. Two compounds acting on the same receptor pathway can sit at very different points on the evidence maturity scale, and this pairing is a clear example of exactly that.
Why GHRH analogue engineering varies so much within the class
Multiple compounds engineered from the same starting point, natural GHRH, with different specific modifications, is a pattern worth understanding rather than treating all GHRH analogues as functionally identical. Different modifications produce different durations, different stability profiles, and potentially different receptor binding characteristics, even within compounds sharing the same fundamental target. Sermorelin is a third GHRH analogue with its own distinct modification history.
Why Healio does not stock CJC-1295
Healio’s GHRH analogue offering is tesamorelin specifically, the compound with the most substantial clinical evidence in this mechanistic family. CJC-1295 is not currently part of the catalog.
Sourcing tesamorelin for research
The verification standard applies without modification: a batch-specific certificate of analysis from a named independent laboratory, purity by HPLC, identity by mass spectrometry, and a lot number matching the vial. A third-party certificate of analysis sets out each field, and every batch is published before purchase.
CJC-1295 ipamorelin: why the two are almost always named together
Search CJC-1295 on its own and you will mostly find CJC-1295 ipamorelin. The pairing is so standard in research discussion that the two names have effectively fused, and it is worth understanding why rather than treating it as marketing habit.
They act on two different receptors. CJC-1295 is a GHRH analogue, so it works on the growth hormone releasing hormone receptor, the same target tesamorelin hits. Ipamorelin is a growth hormone secretagogue that works on the ghrelin receptor instead. Two separate doors into the same room.
The theory behind combining them is that stimulating both pathways at once produces a larger pulse than either alone, because the pituitary responds to GHRH signalling and ghrelin signalling through partly independent mechanisms. That is a reasonable mechanistic argument, and it is the reason the pairing exists.
What it is not is a demonstrated protocol. The combination has been examined in research contexts, but it does not carry the trial record that an approved compound does, and the two are frequently discussed together in settings that are considerably less rigorous than a clinical study.
What ipamorelin benefits research actually reports
Ipamorelin gets described as the selective one, and there is something behind that description.
Earlier growth hormone secretagogues had a reputation for stimulating cortisol and prolactin alongside growth hormone, which is a problem if growth hormone is the thing you are studying. Ipamorelin was developed with greater selectivity for the growth hormone response specifically, and that selectivity is most of why it displaced the older compounds in research discussion.
The published work is largely preclinical and early-phase. Ipamorelin was investigated in clinical development for postoperative ileus and did not carry through to approval, which is a fairly important detail that rarely appears alongside the enthusiasm. A compound that entered human trials and did not finish them tells you something.
Healio does not stock ipamorelin or CJC-1295. Both are named here because the comparison is the thing people are actually researching, and describing a compound honestly matters more than only describing the ones on the shelf.
CJC-1295 ipamorelin vs tesamorelin: the practical comparison
This is the comparison that decides most research questions in this space, and the deciding factor is not mechanism. It is evidence.
| Tesamorelin | CJC-1295 | Ipamorelin | |
|---|---|---|---|
| Class | GHRH analogue | GHRH analogue | Growth hormone secretagogue |
| Receptor | GHRH receptor | GHRH receptor | Ghrelin receptor |
| Regulatory status | FDA approved for a specific indication | Not approved | Not approved, development discontinued |
| Human trial record | Multiple published trials with imaging endpoints | Limited | Early phase, did not complete |
| Stocked at Healio | Yes | No | No |
Read the approval row. Tesamorelin is the only compound in that table with an approved indication behind it, granted for reducing excess visceral abdominal fat in a specific patient population and measured by CT imaging rather than by self-report. Whatever the mechanistic arguments for the other two, one of them has been through the full process and the others have not.
That is the honest basis for choosing, and it is a very different basis from the one most forum discussion uses.
Why the CJC-1295 modification question keeps coming up
CJC-1295 is discussed in two forms, and confusing them makes the literature unreadable.
The version usually called CJC-1295 with DAC carries a drug affinity complex modification that binds to serum albumin, extending its half life substantially. The version without DAC, often labelled modified GRF 1-29, has a much shorter duration of action.
Those are meaningfully different compounds in terms of how long the signal lasts, and research discussing one does not automatically apply to the other. Vendors are not always careful about which one a vial contains, which is a sourcing problem before it is a research problem.
The general point extends beyond this compound: a name in this category can cover several structural variants, and the certificate of analysis is what tells you which one you have. That is covered in how to read a certificate of analysis.
Why pulsatility is the argument underneath all of this
Growth hormone is not released steadily. It comes in pulses, largely overnight, and the pulsatile pattern appears to matter to how tissue responds rather than being an incidental feature of the system.
That is the mechanistic case for GHRH analogues and secretagogues generally over administering growth hormone directly. Stimulating the pituitary to release its own hormone preserves something closer to the natural rhythm, including the feedback loops that shut the signal off. Supplying the hormone from outside overrides all of that.
Whether the distinction produces different outcomes in practice is a genuinely open question, and it is the question this whole compound class exists to answer. The wider picture is in growth hormone peptides and peptides vs HGH.
What a CJC-1295 ipamorelin comparison cannot tell you
It cannot tell you that the combination is safe, because the combination has not been characterised for safety in the way an approved compound has.
It cannot tell you a dose. Protocols circulating for this pairing are not derived from trials, and this page is not going to publish one.
And it cannot tell you what is in an unverified vial. Two compounds means two opportunities for the material to be wrong, and a blended vial makes independent verification harder rather than easier. That problem is covered in the GLOW and KLOW blend comparison.
How to read a CJC-1295 ipamorelin claim critically
Three questions cut through most of what circulates about this pairing.
First, which CJC-1295 is being discussed? With DAC and without DAC behave differently in duration, and an article that does not specify is either careless or repackaging someone else’s careless article. That single detail is a reliable quality filter.
Second, is the claim about the combination or about one component? A great deal of writing attributes findings from ipamorelin research to the pairing, or the reverse. Combined administration has not been studied to the standard that either compound has individually, thin as that standard already is.
Third, what is the endpoint? Growth hormone release is a measurable thing and it is not the same as a body composition outcome, a recovery outcome, or anything a person would notice. A compound can raise a hormone level reliably and still have no demonstrated effect on the thing the marketing is selling.
That third question is the one that separates the tesamorelin evidence from the rest of this class. Its trials measured visceral adipose tissue by CT scan, which is an outcome rather than a proxy for one.
Sourcing when the compound you want is not the compound with evidence
This comes up honestly and often enough to address directly.
If a research question genuinely calls for CJC-1295 or ipamorelin, Healio is not the supplier, and the sourcing standard does not change because we are not selling it. A batch certificate published before purchase, HPLC purity stated as a figure, identity confirmed by mass spectrometry, a lot number matching the vial, and a named testing laboratory. For CJC-1295 specifically, add one more: confirmation of whether the material is the DAC version.
Vendors who cannot answer that last question are selling a name rather than a compound.
Where tesamorelin is the right fit, every batch we ship carries a certificate published on the product page before the order button, and the full set is documented before purchase.
Tesamorelin vs CJC-1295: frequently asked questions
What is the difference between tesamorelin and CJC-1295?
Both are GHRH analogues acting on the same receptor pathway with different specific structural modifications. Tesamorelin has completed clinical development and holds a narrow approval; CJC-1295 has not and holds no approved formulation.
Does Healio sell CJC-1295?
No. Healio stocks tesamorelin as its GHRH analogue offering.
Why does CJC-1295 sometimes refer to different products?
It is frequently discussed alongside an additional modification extending duration further, and different sources may describe different specific variants under the same general name.
Do tesamorelin and CJC-1295 have the same evidence base?
No, despite sharing a receptor target. Tesamorelin underwent full clinical development resulting in approval for a narrow indication. CJC-1295 has not undergone comparable development.
The compounds named here, all shipped with batch certificates published up front: retatrutide. The weight loss peptide collection holds the rest of the range.
What is CJC-1295 ipamorelin?
A pairing of two compounds acting on different receptors. CJC-1295 is a GHRH analogue working on the growth hormone releasing hormone receptor; ipamorelin is a secretagogue working on the ghrelin receptor. The theory is that stimulating both produces a larger pituitary response than either alone.
Is CJC-1295 ipamorelin better than tesamorelin?
The research does not establish that. Tesamorelin is the only compound of the three with an approved indication and published trials using imaging endpoints. The pairing has a mechanistic argument behind it and a much thinner evidence record.
What is the difference between CJC-1295 with and without DAC?
The DAC version carries a drug affinity complex modification that binds serum albumin and substantially extends its duration. The version without it, often labelled modified GRF 1-29, acts over a much shorter window. Research on one does not automatically apply to the other.
Same target, different evidence entirely
Sharing a receptor pathway tells you two compounds act through a similar mechanism. It tells you nothing about how much each has actually been studied, and tesamorelin and CJC-1295 illustrate that gap clearly. The weight loss collection stocks tesamorelin, every batch independently tested before it ships.
Related reading
- Tesamorelin Peptide, the compound Healio stocks.
- Growth Hormone Peptides, the mechanistic family explained.
- Sermorelin Peptide, a third GHRH analogue in the same family.